Antineoplastic Agents: Cytotoxic Agents: Antimetabolites
OXELO1 “Xeloda tablet” 500 mg/tab
適應症：可治療轉移性大腸（結腸直腸）癌病患。作為第三期結腸癌患者手術後輔助性療法。與docetaxel併用於治療對anthracycline化學治療無效之局部晚期或轉移性乳癌病患。亦可單獨用於對紫杉醇（taxane）及anthracycline化學治療無效，或無法使用anthracycline治療之局部晚期或轉移性乳癌病患。合併platinum可使用於晚期胃癌之第一線治療。
Usual dose:
Breast cancer
Monotherapy: 2,500 mg/m2 PO divided twice daily for 2 wks followed by 1 wk off, given as 3-wk cycles;
Combination therapy: 2,500 mg/m2 PO divided twice daily for 2 wks followed by 1 wk off, given as 3-wk cycles in combination with docetaxel 75 mg/m2 IV over 1 h q3w. Premedication for docetaxel should be initiated prior to starting therapy.
Colorectal cancer: 2,500 mg/m2 divided twice daily for 2 wks followed by 1 wk off, given as 3-wk cycles; Colorectal cancer, adjuvant (monotherapy): 2,500 mg/m2 divided twice daily for 2 wks followed by 1 wk off, given as 3-wk cycles.
Dose adjustment:
Renal impairment: CrCl 30-50 ml/min, decrease starting dose to 75% of the original dose.
Adverse effect:
Common: abdominal pain, anorexia, constipation, N/V, stomatitis, dermatitis, fatigue.
Serious: neutropenia, thrombocytopenia, diarrhea, hand/foot syndrome, hyperbilirubinemia, myocardial infarction.
健保使用規範：（88/10/1、91/4/1、92/6/1、93/8/1、96/9/1、97/12/1）
1.capecitabine與docetaxel併用於治療對anthracycline化學治療無效之局部晚期或轉移性乳癌病患。
2.單獨用於對taxanes及anthracycline化學治療無效，或無法使用anthracycline治療之局部晚期或轉移性乳癌病患。
3.治療轉移性結腸直腸癌的第一線用藥。（92/6/1）
4.第三期結腸癌患者手術後的輔助性療法，以八個療程為限。（96/9/1）
5.Capecitabine合併platinum可使用於晚期胃癌之第一線治療。(97/12 /1 )